Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Zydus Cadila gets USFDA nod for blood pressure drug

Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure. The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg.

April 09, 2021 / 04:55 PM IST

Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure. The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg.

"The combination drug is used for the treatment of high blood pressure. It is is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide," Zydus said in a BSE filing.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in 2003-04.

Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare therapies.

PTI
first published: Jun 30, 2018 04:35 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347